Skip to main content
S&P 5007,764.640.00%DOW51,863.69-0.36%NASDAQ27,244.28+0.45%BTC$86,256.00-0.07%ETH$2,758.58-0.49%GOLD$4,402.30+0.59%OIL$89.71-0.89%
Smart Investors Daily
BioMarin Pharmaceutical Inc. logo

NASDAQ · BMRN

BioMarin Pharmaceutical Inc.

Healthcare · Biotechnology

$64.06

Down-$0.69 (-1.08%)

Updated Sep 22, 2026, 10:52 PM

SID Score

6.0/10

Composite research score

Smart Money

54/100

Neutral

Market cap
10.18B
P/E ratio
19.56
Dividend yield
0.00%
52-week range
$49.26 – $70.98
Volume
1.88M
Avg. volume
2.67M

Price performance

BMRN price history

1M range · 20 trading sessions · Daily adjusted prices

BMRN closed at $64.06 after 20 trading sessions, down 1.55% for the selected period.

Last close
$64.06
Period change
-1.55%
Period low
$63.94
Period high
$66.97
Daily close
View OHLC price history
BMRN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 21, 2026$64.35$64.96$63.58$64.061.88M
Sep 18, 2026$65.25$65.29$63.84$63.944.46M
Sep 17, 2026$65.34$66.21$64.97$65.081.38M
Sep 16, 2026$64.48$65.67$64.34$64.732.25M
Sep 15, 2026$65.78$65.78$63.85$64.451.85M
Sep 14, 2026$66.27$66.88$65.72$66.411.34M
Sep 11, 2026$65.96$66.05$65.285$65.681.6M
Sep 10, 2026$64.41$65.59$63.5742$65.512.2M
Sep 9, 2026$63.83$65.325$63.64$64.411.95M
Sep 8, 2026$65.24$66.26$64.01$64.631.46M
Sep 4, 2026$65.785$66.64$65.52$66.532.3M
Sep 3, 2026$67.30$67.695$66.32$66.431.48M
Sep 2, 2026$65.00$67.20$64.99$66.972.52M
Sep 1, 2026$65.54$66.015$64.49$64.841.78M
Aug 31, 2026$65.95$66.2972$64.33$65.232.3M
Aug 28, 2026$64.99$65.08$64.07$64.6651.1M
Aug 27, 2026$65.28$65.915$64.83$65.291.25M
Aug 26, 2026$65.62$66.5322$65.33$65.611.88M
Aug 25, 2026$65.03$66.36$65.02$66.121.36M
Aug 24, 2026$66.57$67.18$64.71$65.072.26M

Latest BMRN news

The latest Smart Investors Daily articles mentioning BMRN.

Stock researchCompany · Overview

BMRN research

Overview

Company profile and research snapshot.

Company profile

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$80.58
Implied upside
—
Analysts
—
BMRN recent ratings
DateFirmRatingTarget
Sep 10, 2026HC Wainwright & Co.Neutral—
Sep 1, 2026Piper SandlerOverweight—
Aug 31, 2026HC Wainwright & Co.Neutral—
Aug 31, 2026JefferiesBuy—
Aug 19, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 19, 2026

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?

BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite...

Yahoo · Sep 19, 2026

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?

BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...

Yahoo · Sep 18, 2026

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By